Anupam Rasayan's deputy CFO discussed the company's acquisition of a 50% stake in Bliss GVS Pharma, marking its entry into finished dosage pharmaceutical formulations

Wed 30 Sep 2026

Stake acquired in Bliss

50 percent

Initial promoter stake bought

48.2 percent

Current utilization level

30 percent

Target utilization level

60 to 70 percent

Current revenue

1,000 crores rupees

Heard on Live TV News Channel between 09:59:25 - 10:02:25 IST.

• Deputy CFO Vishal Tucker said Anupam acquired 48.2% stake from promoter and a large shareholder, plus another ~2%, taking total holding to 50% in Bliss GVS Pharma
• Said Bliss will become a subsidiary with line-by-line consolidation while remaining separately listed
• Said Bliss's manufacturing utilization is currently 30% with UGMP, USFDA and WHO GMP certifications, targeted to rise to 60-70%
• Said Bliss's revenue could grow from around 1,000 crores towards 2,000-3,000 crores over two to three years, with new CEO Rahul Atukmore
• Said growth would come from US, Europe, India and CIS markets, plus a CDMO offering combining Anupam and Bliss, and possible inorganic API expansion

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.